Neurodegenerative disease management最新文献

Exploring the mid-term impact of telemonitoring in Parkinson's disease: insights from adoption into clinical practice. 探索远程监控在帕金森病中的中期影响：从采用到临床实践的见解。

IF 3.4

Neurodegenerative disease management Pub Date : 2025-10-15 DOI: 10.1080/17582024.2025.2562754

Foivos S Kanellos, Eleni Kosmidi, Georgios Rigas, Ermioni Petkou, Yannis V Simos, Lampros Lakkas, Dimitrios Peschos, Spyridon Konitsiotis, Konstantinos I Tsamis

{"title":"Exploring the mid-term impact of telemonitoring in Parkinson's disease: insights from adoption into clinical practice.","authors":"Foivos S Kanellos, Eleni Kosmidi, Georgios Rigas, Ermioni Petkou, Yannis V Simos, Lampros Lakkas, Dimitrios Peschos, Spyridon Konitsiotis, Konstantinos I Tsamis","doi":"10.1080/17582024.2025.2562754","DOIUrl":"https://doi.org/10.1080/17582024.2025.2562754","url":null,"abstract":"Background: Routine clinical evaluations offer limited insight into daily variability and disease progression in Parkinson's disease (PD). While wearable devices are increasingly used to improve patient monitoring, evidence of their effectiveness remains scarce.Objective: To assess the efficacy of integrating a telemonitoring system into standard clinical procedures, highlighting its role in enabling efficient, patient-centered treatment adjustments.Methods: Thirty-five PD patients were monitored for 6 months using a telemonitoring device alongside standard care. Disease progression was assessed via MDS-UPDRS part III (UPDRS-p3) and device-reported outcomes (dUPDRS) at baseline and follow-up. Physicians provided feedback on telemedicine utility.Results: UPDRS-p3 scores improved by 1.9-5.63 points. Changes in UPDRS-p3 strongly correlated with dUPDRS (r = 0.82). Sixty-two percent of patients had treatment modifications, 36% of which occurred remotely.Conclusion: Telemonitoring supported clinical decisions, detected subtle symptom changes, and offered valuable insights for improving motor symptoms and patient management.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-7"},"PeriodicalIF":3.4,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145293176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune system modifications in atypical parkinsonism related to autoimmunity - a case control study. 非典型帕金森病与自身免疫相关的免疫系统改变-一项病例对照研究。

IF 3.4

Neurodegenerative disease management Pub Date : 2025-10-14 DOI: 10.1080/17582024.2025.2573597

Annamma Mathai, Sudheeran Kannoth, Vivek Nambiar, Siby Gopinath, Meena Thevarkalam, Anandkumar Anandakuttan, Sugavanan Kalingavarman, Ullas Mony, Manu Raj, Renjitha Bhaskaran

{"title":"Immune system modifications in atypical parkinsonism related to autoimmunity - a case control study.","authors":"Annamma Mathai, Sudheeran Kannoth, Vivek Nambiar, Siby Gopinath, Meena Thevarkalam, Anandkumar Anandakuttan, Sugavanan Kalingavarman, Ullas Mony, Manu Raj, Renjitha Bhaskaran","doi":"10.1080/17582024.2025.2573597","DOIUrl":"https://doi.org/10.1080/17582024.2025.2573597","url":null,"abstract":"Background: Inflammation is known in atypical parkinsonism (AP), but the role of autoimmunity is unclear. This study evaluates immune system modifications suggesting autoimmunity in AP.Methods: Included patients with AP diagnosed at Amrita Institute of Medical Sciences, Kochi (December 2018-May 2019), and age- and sex-matched controls. Fifteen immune parameters, including T regulatory cells, RORγt, and cytokines (IL-2, IL-4, IL-6, IL-10, IL-17A, IL-21, IL-22, IL-23, TNF, IFN-γ, GM-CSF, NF-κB, TGF-β), were assessed in peripheral blood (flow cytometry and ELISA).Results: Twenty-six cases (mean age 67.8 ± 7.5 years; 16 males) and 15 controls (mean age 68.1 ± 3.5 years; 10 males) studied. Diagnoses included progressive supranuclear palsy (n = 15), multiple system atrophy (n = 1), frontotemporal dementia with parkinsonism (n = 2), and unspecified AP (n = 8). AP cases had significantly higher RORγt (p = 0.041), IL-6 (p = 0.004), TNF (p = 0.020), IL-10 (p = 0.027), and IL-4 (p = 0.048).Conclusions: Elevated RORγt and cytokines suggest immune dysregulation and possible autoimmune mechanisms in AP, warranting further investigation.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-6"},"PeriodicalIF":3.4,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145286421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient and healthcare provider experience of diroximel fumarate: considerations for selecting disease-modifying therapy. 富马酸地洛西梅尔的患者和医疗保健提供者的经验：选择疾病改善治疗的考虑。

IF 3.4

Neurodegenerative disease management Pub Date : 2025-10-06 DOI: 10.1080/17582024.2025.2564589

Cortnee Roman, Meghan Garabedian, Virginia R Schobel, Beth Schneider, Elizabeth Luce, Jason P Mendoza, James B Lewin, Sai L Shankar

{"title":"Patient and healthcare provider experience of diroximel fumarate: considerations for selecting disease-modifying therapy.","authors":"Cortnee Roman, Meghan Garabedian, Virginia R Schobel, Beth Schneider, Elizabeth Luce, Jason P Mendoza, James B Lewin, Sai L Shankar","doi":"10.1080/17582024.2025.2564589","DOIUrl":"https://doi.org/10.1080/17582024.2025.2564589","url":null,"abstract":"Purpose: To evaluate treatment perceptions of diroximel fumarate (DRF) for relapsing multiple sclerosis (MS), with contextual data from dimethyl fumarate (DMF) users, based on patient and healthcare provider (HCP) surveys.Methods: A prospective web-based survey was conducted among MyMSTeam users aged ≥ 21 years in the United States, who provided information about their MS disease and treatment history. The Spherix HCP survey collected retrospective chart data from HCPs for patients who switched disease-modifying therapies (DMTs).Results: Of 535 MyMSTeam respondents, 77 (14%) received DMF and 46 (9%) received DRF. DRF users reported physical and emotional benefits such as slowed disease progression, decreased relapses, and new symptom prevention, with 70% noting at least one physical benefit and 46% reporting emotional/quality of life benefits. Additionally, 83% found DRF tolerable. HCPs reported prescribing DRF due to good tolerability (58%) and a preference for oral administration (50%). The most common reasons for switching to DRF were lack of efficacy (52%) or poor tolerability (49%) of previous DMTs.Conclusion: A real-world, patient-focused survey on MS treatment suggested DRF was well tolerated and associated with patient-reported physical benefits. HCP-reported reasons for selecting DRF included efficacy and tolerability issues with prior DMT.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"1-11"},"PeriodicalIF":3.4,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145239294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multiple sclerosis as a genetic risk factor for Alzheimer's disease: Insights from Mendelian randomisation. 多发性硬化症是阿尔茨海默病的遗传风险因素：孟德尔随机化的见解。

IF 3.4

Neurodegenerative disease management Pub Date : 2025-10-01 Epub Date: 2025-07-20 DOI: 10.1080/17582024.2025.2530350

Jai Kumar Rajavoor Muniswamy, Amrutha Reshi, Dibyendu Roy Chowdhury, Praveen Kumar-M

{"title":"Multiple sclerosis as a genetic risk factor for Alzheimer's disease: Insights from Mendelian randomisation.","authors":"Jai Kumar Rajavoor Muniswamy, Amrutha Reshi, Dibyendu Roy Chowdhury, Praveen Kumar-M","doi":"10.1080/17582024.2025.2530350","DOIUrl":"10.1080/17582024.2025.2530350","url":null,"abstract":"Background: Inflammation is implicated in neurodegeneration, but the causal link between multiple sclerosis and Alzheimer's disease remains unclear.Objective: To investigate the genetic relationship between MS and AD using Mendelian Randomization and assess downstream molecular effects.Methods: Two-sample MR was conducted using GWAS summary statistics, with IVW and MR Egger methods. Sensitivity analyses assessed pleiotropy and heterogeneity. eQTL and KEGG pathway analyses explored gene expression and functional relevance.Results: Sixty-four SNPs from European MS GWAS were selected for MR analysis; an African American dataset showed no significant SNPs. IVW and MR-Egger indicated a positive causal association between MS and AD (p < 0.05). Pleiotropy (Egger β = -0.017, p = 0.002) was addressed using robust methods. eQTL analysis identified 41 genes, with KEGG enrichment implicating Th1/Th2 and Th17 differentiation pathways.Conclusion: MS may increase AD risk via shared T-cell - mediated immunogenetic mechanisms.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"209-221"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12456208/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Survival rates in frontotemporal dementia and Alzheimer's disease. 额颞叶痴呆和阿尔茨海默病的存活率

IF 3.4

Neurodegenerative disease management Pub Date : 2025-10-01 Epub Date: 2025-07-02 DOI: 10.1080/17582024.2025.2527553

David Foxe, James Muggleton, Sau Chi Cheung, Nicole Mueller, Rebekah M Ahmed, Manisha Narasimhan, James R Burrell, Yun Tae Hwang, Nicholas J Cordato, Olivier Piguet

{"title":"Survival rates in frontotemporal dementia and Alzheimer's disease.","authors":"David Foxe, James Muggleton, Sau Chi Cheung, Nicole Mueller, Rebekah M Ahmed, Manisha Narasimhan, James R Burrell, Yun Tae Hwang, Nicholas J Cordato, Olivier Piguet","doi":"10.1080/17582024.2025.2527553","DOIUrl":"10.1080/17582024.2025.2527553","url":null,"abstract":"Aim: To evaluate the survival rates in well-characterized cohorts of frontotemporal dementia (FTD) subtypes - behavioral variant (bvFTD), progressive nonfluent aphasia (PNFA), and semantic dementia (SD) - and both typical (amnestic) and atypical (aphasic: logopenic progressive aphasia [LPA]) presentations of Alzheimer's disease (AD).Patients & methods: Three hundred and twenty-one participants (54 bvFTD, 26 PNFA, 22 SD, 20 LPA, 32 AD, 167 controls) were recruited. Patients underwent a comprehensive baseline assessment and annual reviews. Survival data were analyzed using Kaplan-Meier curves and Cox proportional hazard models.Results: Median survival from symptom onset was longest in SD (11.9 years) and shortest in LPA (7 years). Median survival for the bvFTD, PNFA, and AD groups was 8.7, 8.6, and 10 years, respectively. SD survival was significantly longer than PNFA and AD. Female sex was associated with shorter survival in LPA. Shorter symptom duration at baseline assessment was related to shorter survival in bvFTD, SD, LPA, and AD. Lower overall cognition in bvFTD, LPA, and AD, and worse functional outcomes in SD and AD at baseline were associated with shorter survival.Conclusions: Our findings demonstrate distinct survival patterns across FTD and AD subtypes. Demographic and presenting clinical features provide valuable prognostic insights for survival.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"191-197"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12456210/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144541468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent and on-going trials for the treatment of levodopa-induced dyskinesia: a review of the clinical trial databases. 最近和正在进行的治疗左旋多巴诱导的运动障碍的试验：临床试验数据库综述。

IF 3.4

Neurodegenerative disease management Pub Date : 2025-10-01 Epub Date: 2025-07-05 DOI: 10.1080/17582024.2025.2528557

Jawad Al-Kassmy, Mohammed Alsalmi, Woojin Kang, Michael Palayew, Philippe Huot

{"title":"Recent and on-going trials for the treatment of levodopa-induced dyskinesia: a review of the clinical trial databases.","authors":"Jawad Al-Kassmy, Mohammed Alsalmi, Woojin Kang, Michael Palayew, Philippe Huot","doi":"10.1080/17582024.2025.2528557","DOIUrl":"10.1080/17582024.2025.2528557","url":null,"abstract":"L-3,4-dihydroxyphenylalanine (Levodopa)-induced dyskinesia remains a condition for which there are few therapeutic options available. Fortunately, the past 5 years have seen the completion of several clinical trials, some of which yielded positive and encouraging results. Here, we performed a review of the clinical trials that were completed or for which outcomes were disclosed within the past 5 years. Promising results were obtained in Phase II trials with the serotonin type 1A (5-HT1A) agonist befiradol, the dopamine D3 receptor antagonist mesdopetam and the phosphodiesterase inhibitor CPL500036. In contrast, the metabotropic glutamate 4 (mGlu4) receptor negative allosteric modulator foliglurax and JM-010 (a combination of the 5-HT1A partial agonist buspirone and the and the 5-HT type 1B and 1D [5-HT1B/1D] agonist zolmitriptan) did not meet their endpoints in Phase II studies. Lastly, robot-assisted Repetitive Transcranial Magnetic Stimulation (rTMS) of the pre-supplementary motor area may be a promising non-pharmacological approach to alleviate dyskinesia.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"235-244"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12456213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gait analysis for Parkinson's disease using multiscale entropy. 基于多尺度熵的帕金森病步态分析。

IF 3.4

Neurodegenerative disease management Pub Date : 2025-10-01 Epub Date: 2025-05-26 DOI: 10.1080/17582024.2025.2510842

Leianne Rose V Amisola, Ralph Joaquimn B Acosta, Hail Mariella D Arao-Arao, Vianca Nicole C Benitez, Ron Marrion T Chan, Anna Katrina G Co, Nicole Shandy F Cortez, Pj Brian F Galina, Michael Christian A Virata

{"title":"Gait analysis for Parkinson's disease using multiscale entropy.","authors":"Leianne Rose V Amisola, Ralph Joaquimn B Acosta, Hail Mariella D Arao-Arao, Vianca Nicole C Benitez, Ron Marrion T Chan, Anna Katrina G Co, Nicole Shandy F Cortez, Pj Brian F Galina, Michael Christian A Virata","doi":"10.1080/17582024.2025.2510842","DOIUrl":"10.1080/17582024.2025.2510842","url":null,"abstract":"Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by motor dysfunction and complex gait abnormalities. Traditional linear methods often fail to capture the intricate movement patterns in PD. This review highlights Multiscale Entropy (MSE) as a promising tool for assessing gait dynamics, offering deeper insights into movement variability across multiple temporal scales. MSE distinguishes healthy and pathological gait patterns, enhancing early diagnosis and disease monitoring. Advances in wearable sensors, artificial intelligence, and machine learning have boosted MSE's clinical relevance by enabling real-time, personalized gait assessments. Despite these benefits, MSE faces challenges such as computational demands and the need for high-resolution data. Addressing these limitations through large-scale studies, standardized protocols, and integration of emerging technologies may support broader clinical adoption and the development of a robust normative database.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"245-258"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12456205/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Outcomes of older patients with multiple sclerosis treated with interferon beta-1a or peginterferon beta-1a in MS PATHS. 老年多发性硬化症患者接受干扰素β -1a或聚乙二醇干扰素β -1a治疗的结果

IF 3.4

Neurodegenerative disease management Pub Date : 2025-10-01 Epub Date: 2025-07-15 DOI: 10.1080/17582024.2025.2527558

Le H Hua, Carrie M Hersh, Lana Zhovtis Ryerson, Nick Belviso, Megan Vignos

引用次数: 0

Experiences of patient and care partner dyads in early Alzheimer's disease: a mixed-method study in the United States. 早期阿尔茨海默病患者和护理伙伴的经验：在美国进行的一项混合方法研究。

IF 3.4

Neurodegenerative disease management Pub Date : 2025-10-01 Epub Date: 2025-08-05 DOI: 10.1080/17582024.2025.2542700

Lei Lv, Elnara Fazio-Eynullayeva, Paul Mystkowski, Caroline McKay, Tamara Al-Zubeidi, Jordan Miller, Stephanie McKee, Catherine Bottomley, Catherine Floegel, Richard Hyde, Abdalla Aly

{"title":"Experiences of patient and care partner dyads in early Alzheimer's disease: a mixed-method study in the United States.","authors":"Lei Lv, Elnara Fazio-Eynullayeva, Paul Mystkowski, Caroline McKay, Tamara Al-Zubeidi, Jordan Miller, Stephanie McKee, Catherine Bottomley, Catherine Floegel, Richard Hyde, Abdalla Aly","doi":"10.1080/17582024.2025.2542700","DOIUrl":"10.1080/17582024.2025.2542700","url":null,"abstract":"Aims: Understanding the holistic experience of patients with early Alzheimer's disease (AD) and their care partners is important to identify unmet needs. This study aimed to describe and compare patient-care partner dyad experiences and perspectives in early AD.Patients & methods: Experiences of patients and their care partners (dyads) were explored using a survey, qualitative interviews, and social media listening. Each dyad completed a 25-minute quantitative online survey exploring their perceptions of symptoms, comorbidity impact, financial burden, and preferred treatment characteristics. Data were analyzed descriptively and comparatively.Results: 150 patient-care partner dyads completed the survey. Patients and care partners frequently reported memory-related issues and cognitive challenges (68% and 77%, respectively); approximately 19% of responses were discordant, with patients often under-reporting symptoms. Managing comorbidities worsened overall well-being of patients (41%) and care partners (40%). Treatments slowing AD progression (patients: 99%; care partners: 96%) and improving symptoms (patients: 95%; care partners: 93%) were important. Approximately 26% of respondents experienced significant negative financial impacts.Conclusions: Patients and care partners perceived early AD impacts similarly whereas some symptoms were perceived differently. There was a shared desire for disease-modifying treatments. Limited financial impact may reflect preserved functionality and limited use of disease-modifying treatments.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":" ","pages":"223-234"},"PeriodicalIF":3.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12456212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144789616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Care partners of people with dementia: the role of the "waiting room". 痴呆症患者的护理伙伴：“候诊室”的作用。

IF 3.4

Neurodegenerative disease management Pub Date : 2025-10-01 Epub Date: 2025-08-04 DOI: 10.1080/17582024.2025.2542659

Francesca Bosinelli, Andrea Brugnolo, Nicola Girtler, Matteo Pardini, Gabriella Biffa, Francesca Riccardi

引用次数: 0